EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Levels of Natural Antibodies Before and After Immunoglobulin Replacement Treatment Affect the Clinical Phenotype in Common Variable Immunodeficiency

Ioannis Sarrigeorgiou, Gerasimina Tsinti, Fani Kalala, Anastasios Germenis, Matthaios Speletas, Peggy Lymberi

Journal of Clinical Immunology · 2025

DOI: 10.1007/s10875-024-01805-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology, 2025. Verfasst von Ioannis Sarrigeorgiou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunology, Department of Immunology, Hellenic Pasteur Institute, Athens, Greece. Hauptthemen laut MEDLINE: Common Variable Immunodeficiency, Immunoglobulin M, Phenotype, Immunoglobulin G. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural antibodies (NAbs) occurring in individuals without prior exposure to specific antigens, provide direct first barrier protection against pathogens, and exert immunoregulation thus actively contributing to the maintenance of immune homeostasis, controlling inflammatory processes and preventing autoimmunity. Common variable immunodeficiency (CVID) is a heterogeneous group of disorders characterized by a compromised immune function that brings into focus the role of NAbs. Our aim was to explore whether NAb levels could serve as potential key indicators in CVID for monitoring disease progression and predicting outcomes. In this study, we analyzed a Hellenic cohort of 56 patients with CVID (31 newly diagnosed and 25 under immunoglobulin replacement therapy-IgRT) and 33 healthy controls, for total Ig levels and serum IgM and IgG NAb levels against five informative target-antigens of NAbs, namely, actin, DNA, carbonic anhydrase, F(ab΄)2 fragments of human IgG and TriNitroPhenyl. In addition, follow-up pre- and post- IgRT samples were analyzed in ten (10) patients of our cohort. Results showed that Ig-treated patients exhibited significantly lower IgM NAb levels than untreated patients and healthy controls against all panel antigens. In the follow-up samples, pre-treatment IgM NAb levels negatively correlated with total serum IgM. This imbalance was only partially restored after IgRT, with a significant decrease in IgM NAb levels observed in nine out of ten patients. Moreover, post-treatment patients with recurrent infections presented significantly lower IgM NAb levels, a reduction also observed in patients with bronchiectasis independently of treatment status. On the contrary, post-treatment patients with enteropathy had significantly higher IgM NAb levels against all panel antigens, an increase also noted in patients with autoimmune diseases. Regarding IgG NAbs, replacement therapy restored levels to those of healthy controls. In conclusion, impaired NAb levels are found in CVID patients, particularly related to certain phenotypes. Moreover, the significant decrease in IgM NAb levels after IgRT suggests a potential association with disease course and complications. The results suggest that administration of human IgM NAbs may be an effective combinatorial treatment in selected patients. Further research is needed to understand the functional roles of NAbs in CVID and its complex clinical phenotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Common Variable ImmunodeficiencyImmunoglobulin MPhenotypeImmunoglobulin GHumansFemaleMaleAdultMiddle AgedImmunoglobulins, IntravenousYoung AdultAgedAdolescentTreatment Outcome

Stichwörter der Autor:innen

CVIDClinical phenotypeIgGIgMImmunoglobulin Replacement Treatment (IgRT)Natural Antibodies (NAbs)

Substanzen

Immunoglobulin MImmunoglobulin GImmunoglobulins, Intravenous

Autor:innen und Institutionen

  • Laboratory of Immunology, Department of Immunology, Hellenic Pasteur Institute, Athens, Greece.
  • Department of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, Larissa, Greece.
  • Laboratory of Immunology, Department of Immunology, Hellenic Pasteur Institute, Athens, Greece. plymberi@pasteur.gr.

Zitieren

APA

Sarrigeorgiou, I., Tsinti, G., Kalala, F., Germenis, A., Speletas, M., & Lymberi, P. (2025). Levels of Natural Antibodies Before and After Immunoglobulin Replacement Treatment Affect the Clinical Phenotype in Common Variable Immunodeficiency. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01805-7

Vancouver

Sarrigeorgiou I, Tsinti G, Kalala F, Germenis A, Speletas M, Lymberi P. Levels of Natural Antibodies Before and After Immunoglobulin Replacement Treatment Affect the Clinical Phenotype in Common Variable Immunodeficiency. Journal of Clinical Immunology. 2025. doi:10.1007/s10875-024-01805-7

BibTeX
@article{Sarrigeorgiou2025,
  author = {Sarrigeorgiou, Ioannis and Tsinti, Gerasimina and Kalala, Fani and Germenis, Anastasios and Speletas, Matthaios and Lymberi, Peggy},
  title = {Levels of Natural Antibodies Before and After Immunoglobulin Replacement Treatment Affect the Clinical Phenotype in Common Variable Immunodeficiency},
  journal = {Journal of Clinical Immunology},
  year = {2025},
  doi = {10.1007/s10875-024-01805-7}
}
Kostenlos starten →